Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.34)
# 945
Out of 4,784 analysts
476
Total ratings
41.23%
Success rate
4.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Reiterates: Buy | $13 | $2.91 | +347.46% | 15 | Mar 28, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.80 | - | 13 | Mar 27, 2025 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $10.62 | - | 8 | Mar 24, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $1.58 | +661.90% | 2 | Mar 21, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $0.41 | +2,838.30% | 17 | Mar 19, 2025 | |
| PLRX Pliant Therapeutics | Reiterates: Neutral | n/a | $1.47 | - | 24 | Mar 18, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.91 | +292.67% | 35 | Mar 14, 2025 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $32 | $3.71 | +762.53% | 11 | Mar 13, 2025 | |
| ALGS Aligos Therapeutics | Maintains: Buy | $75 → $70 | $9.12 | +667.54% | 5 | Mar 11, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $24 → $35 | $22.39 | +56.32% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $63 → $60 | $11.58 | +418.13% | 30 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $42.72 | +75.56% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $8.08 | +159.90% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $45.99 | +56.56% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $327.87 | +23.52% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $4.93 | +11.56% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $37.82 | +151.19% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.71 | +215.24% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.67 | +254.22% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $4 | $0.61 | +551.47% | 25 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.50 | +42.86% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.59 | +923.89% | 5 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $22 | $19.68 | +11.79% | 20 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $21.76 | +120.59% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.52 | - | 16 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $2.92 | +156.85% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.26 | +296.83% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $8.29 | +56.82% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.61 | +39,360.70% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.28 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $26.63 | -6.12% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.59 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.32 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $25.65 | -72.71% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.71 | -29.32% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.93 | - | 2 | Feb 15, 2017 |
Inventiva
Mar 28, 2025
Reiterates: Buy
Price Target: $13
Current: $2.91
Upside: +347.46%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.80
Upside: -
Assembly Biosciences
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.62
Upside: -
MetaVia
Mar 21, 2025
Reiterates: Buy
Price Target: $12
Current: $1.58
Upside: +661.90%
Acurx Pharmaceuticals
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.41
Upside: +2,838.30%
Pliant Therapeutics
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Akebia Therapeutics
Mar 14, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.91
Upside: +292.67%
Sagimet Biosciences
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $3.71
Upside: +762.53%
Aligos Therapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $75 → $70
Current: $9.12
Upside: +667.54%
Cidara Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $22.39
Upside: +56.32%
Mar 7, 2025
Maintains: Buy
Price Target: $63 → $60
Current: $11.58
Upside: +418.13%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $42.72
Upside: +75.56%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $8.08
Upside: +159.90%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $45.99
Upside: +56.56%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $327.87
Upside: +23.52%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $4.93
Upside: +11.56%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $37.82
Upside: +151.19%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $5.71
Upside: +215.24%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.67
Upside: +254.22%
Jan 29, 2025
Reiterates: Buy
Price Target: $4
Current: $0.61
Upside: +551.47%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.50
Upside: +42.86%
Jan 21, 2025
Reiterates: Buy
Price Target: $6
Current: $0.59
Upside: +923.89%
Jan 15, 2025
Maintains: Buy
Price Target: $18 → $22
Current: $19.68
Upside: +11.79%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $21.76
Upside: +120.59%
Dec 27, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.52
Upside: -
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $2.92
Upside: +156.85%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.26
Upside: +296.83%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $8.29
Upside: +56.82%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.61
Upside: +39,360.70%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $26.63
Upside: -6.12%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.32
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $25.65
Upside: -72.71%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.71
Upside: -29.32%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.93
Upside: -